Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

BACKGROUND: Platinum-doublet, first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) is limited to 4–6 cycles. An alternative strategy used to prolong the duration of first-line treatment and extend survival in metastatic NSCLC is first-line maintenance therapy. Er...

Descripción completa

Detalles Bibliográficos
Autores principales: Vergnenègre, Alain, Ray, Joshua A, Chouaid, Christos, Grossi, Francesco, Bischoff, Helge G, Heigener, David F, Walzer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278202/
https://www.ncbi.nlm.nih.gov/pubmed/22347803
http://dx.doi.org/10.2147/CEOR.S25923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278202/
https://www.ncbi.nlm.nih.gov/pubmed/22347803
http://dx.doi.org/10.2147/CEOR.S25923

Ejemplares similares